Home » Newsletters » BioWorld Science

BioWorld Science

March 2, 2016

View Archived Issues

Benitec to terminate HCV program

Novel sulfiredoxin inhibitor induces selective death of cancer cells

Lumosa Therapeutics describes novel thrombolytic agent DC-009

EMA committee recommends approval of Idelvion for hemophilia B

Innovate licenses larazotide acetate from Alba Therapeutics

Novel anti-HIV combinectin BMS-986197 may have enhanced resistance profile

Cebranopadol demonstrates significant improvements in lower backpain in phase IIb study

Siemens to release genetic assay for early detection of Zika virus

Jiangsu Chia Tai Tianqing Pharmaceutical Group patents TLR7 agonists

Hydra Biosciences reports development of TRPC5 antagonists

FLAG-003 awarded E.U. orphan drug designation for glioma

MAA submitted for tivozanib as first-line treatment of advanced RCC

Z53 Therapeutics is launched as a novel oncology start-up

Modified version of troponin C modulates cardiac contractility in vivo

Preclinical and phase I results presented for HIV treatment/prophylaxis candidate MK-8591

Polymorphism in galectin-3 lectin domain is associated with beta-lactam allergy

Aytu BioScience and Hybridyne enter study agreement for trial using ProxiScan and ProstaScint

Pfizer initiates phase I study of PF-06801591

FDA approves Odefsey single-tablet regimen for HIV-1 infection

FDA announces new Orphan Products Natural History Grants program

Horizon Discovery and Centauri Therapeutics form Avvinity Therapeutics

Evgen cleared to begin phase II trial of SFX-01 for aneurysmal subarachnoid hemorrhage

ProStrakan signs agreement to acquire Moventig rights in Europe

FDA grants orphan drug designation to BMN-270 gene therapy for hemophilia A

New phase II trial investigates sulfatinib for thyroid cancer

First-in-human study of oral antimalarial drug SJ-733

Hikma closes acquisition of Roxane Laboratories and Boehringer Ingelheim Roxane

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 12, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...